Once a promising pioneer state in ibogaine research for the treatment of opioid use disorder, Kentucky’s appointment of Attorney General Russell Coleman has brought about the removal
Provincetown, Massachusetts has become the seventh municipality to join the growing movement towards decriminalizing psychedelics—plants and fungi. In a significant policy shift, the Provincetown Select Board voted this week
A new article authored by renowned regulatory specialist Dr. Mason Marks, of the Project on Psychedelics Law and Regulation at Harvard Law School, highlights growing concern about the chasm between
Vivek Ramaswamy, Republican presidential candidate who famously said he did not approve of Ohio’s cannabis initititive last week despite expressing support for federal legalization, is now saying that if elected
Following our previous roundup, numerous states are moving the discussion around psychedelics reform whether through decriminalization, legalization or rescheduling proposals or ancillary measures to access to
The U.S. Court of Appeals for the Ninth Circuit ruled against the Drug Enforcement Administration (DEA) in a psilocybin rescheduling lawsuit. Washington State physician Dr. Sunil
Psychedelic venture studio Beckley Waves has acquired ketamine-assisted therapy provider Nue Life and will continue its work by offering safe and scalable access to treatment with an
A hearing of the House VA’s subcommittee on Health around the use of psychedelic-assisted therapies for mental health disorders originally scheduled for Thursday was postponed following the ongoing failed
NY Mets owner billionaire Steve Cohen has bought as many as 119,092,680 ordinary shares of clinical-stage biopharmaceutical company Bionomics Limited BNOX through his Point72 Asset Management firm,
After the usual 30-day review period, the Food and Drug Administration (FDA) placed GH Research’s GHRS Investigational New Drug (IND) application for a Phase 1 clinical trial of